These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

862 related articles for article (PubMed ID: 32104496)

  • 1. The c-Myc/miR-27b-3p/ATG10 regulatory axis regulates chemoresistance in colorectal cancer.
    Sun W; Li J; Zhou L; Han J; Liu R; Zhang H; Ning T; Gao Z; Liu B; Chen X; Ba Y
    Theranostics; 2020; 10(5):1981-1996. PubMed ID: 32104496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exosome-transmitted miR-128-3p increase chemosensitivity of oxaliplatin-resistant colorectal cancer.
    Liu T; Zhang X; Du L; Wang Y; Liu X; Tian H; Wang L; Li P; Zhao Y; Duan W; Xie Y; Sun Z; Wang C
    Mol Cancer; 2019 Mar; 18(1):43. PubMed ID: 30890168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The HSF1/miR-135b-5p axis induces protective autophagy to promote oxaliplatin resistance through the MUL1/ULK1 pathway in colorectal cancer.
    Wang H; Wang X; Zhang H; Deng T; Liu R; Liu Y; Li H; Bai M; Ning T; Wang J; Ge S; Ba Y
    Oncogene; 2021 Jul; 40(28):4695-4708. PubMed ID: 34140641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. miR-506 enhances the sensitivity of human colorectal cancer cells to oxaliplatin by suppressing MDR1/P-gp expression.
    Zhou H; Lin C; Zhang Y; Zhang X; Zhang C; Zhang P; Xie X; Ren Z
    Cell Prolif; 2017 Jun; 50(3):. PubMed ID: 28217977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MiR-483-3p regulates oxaliplatin resistance by targeting FAM171B in human colorectal cancer cells.
    Liang H; Xu Y; Zhang Q; Yang Y; Mou Y; Gao Y; Chen R; Chen C; Dai P
    Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):725-736. PubMed ID: 30861353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Plasma microRNA miR-1914* and -1915 Suppresses Chemoresistant in Colorectal Cancer Patients by Down-regulating NFIX.
    Hu J; Cai G; Xu Y; Cai S
    Curr Mol Med; 2016; 16(1):70-82. PubMed ID: 26695693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. circHIPK3 promotes oxaliplatin-resistance in colorectal cancer through autophagy by sponging miR-637.
    Zhang Y; Li C; Liu X; Wang Y; Zhao R; Yang Y; Zheng X; Zhang Y; Zhang X
    EBioMedicine; 2019 Oct; 48():277-288. PubMed ID: 31631038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disruption of the c-Myc/miR-200b-3p/PRDX2 regulatory loop enhances tumor metastasis and chemotherapeutic resistance in colorectal cancer.
    Lv Z; Wei J; You W; Wang R; Shang J; Xiong Y; Yang H; Yang X; Fu Z
    J Transl Med; 2017 Dec; 15(1):257. PubMed ID: 29258530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EVs delivery of miR-1915-3p improves the chemotherapeutic efficacy of oxaliplatin in colorectal cancer.
    Xiao Z; Liu Y; Li Q; Liu Q; Liu Y; Luo Y; Wei S
    Cancer Chemother Pharmacol; 2021 Dec; 88(6):1021-1031. PubMed ID: 34599680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. miR-200b-3p mitigates oxaliplatin resistance via targeting TUBB3 in colorectal cancer.
    Wu YZ; Lin HY; Zhang Y; Chen WF
    J Gene Med; 2020 Jul; 22(7):e3178. PubMed ID: 32092782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. miR-29c-3p inhibits autophagy and cisplatin resistance in ovarian cancer by regulating FOXP1/ATG14 pathway.
    Hu Z; Cai M; Zhang Y; Tao L; Guo R
    Cell Cycle; 2020 Jan; 19(2):193-206. PubMed ID: 31885310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Downregulation of microRNA-27b-3p enhances tamoxifen resistance in breast cancer by increasing NR5A2 and CREB1 expression.
    Zhu J; Zou Z; Nie P; Kou X; Wu B; Wang S; Song Z; He J
    Cell Death Dis; 2016 Nov; 7(11):e2454. PubMed ID: 27809310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. miR-409-3p sensitizes colon cancer cells to oxaliplatin by inhibiting Beclin-1-mediated autophagy.
    Tan S; Shi H; Ba M; Lin S; Tang H; Zeng X; Zhang X
    Int J Mol Med; 2016 Apr; 37(4):1030-8. PubMed ID: 26935807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MiR-27b-3p promotes migration and invasion in colorectal cancer cells by targeting HOXA10.
    Yang X; Chen J; Liao Y; Huang L; Wen C; Lin M; Li W; Zhu Y; Wu X; Iwamoto A; Wang Z; Liu H
    Biosci Rep; 2019 Dec; 39(12):. PubMed ID: 31763673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High expression of microRNA-625-3p is associated with poor response to first-line oxaliplatin based treatment of metastatic colorectal cancer.
    Rasmussen MH; Jensen NF; Tarpgaard LS; Qvortrup C; Rømer MU; Stenvang J; Hansen TP; Christensen LL; Lindebjerg J; Hansen F; Jensen BV; Hansen TF; Pfeiffer P; Brünner N; Ørntoft TF; Andersen CL
    Mol Oncol; 2013 Jun; 7(3):637-46. PubMed ID: 23506979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNA-425-5p regulates chemoresistance in colorectal cancer cells via regulation of Programmed Cell Death 10.
    Zhang Y; Hu X; Miao X; Zhu K; Cui S; Meng Q; Sun J; Wang T
    J Cell Mol Med; 2016 Feb; 20(2):360-9. PubMed ID: 26647742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GDPD5, a target of miR-195-5p, is associated with metastasis and chemoresistance in colorectal cancer.
    Feng C; Zhang L; Sun Y; Li X; Zhan L; Lou Y; Wang Y; Liu L; Zhang Y
    Biomed Pharmacother; 2018 May; 101():945-952. PubMed ID: 29635904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MiR-153-5p promotes sensibility of colorectal cancer cells to oxaliplatin via targeting Bcl-2-mediated autophagy pathway.
    He Y; Zhang L; Tan F; Wang LF; Liu DH; Wang RJ; Yin XZ
    Biosci Biotechnol Biochem; 2020 Aug; 84(8):1645-1651. PubMed ID: 32380907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overexpression of MEG3 sensitizes colorectal cancer cells to oxaliplatin through regulation of miR-141/PDCD4 axis.
    Wang H; Li H; Zhang L; Yang D
    Biomed Pharmacother; 2018 Oct; 106():1607-1615. PubMed ID: 30119236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel exosomal miR-46146 transfer oxaliplatin chemoresistance in colorectal cancer.
    Xu Y; Zhu M
    Clin Transl Oncol; 2020 Jul; 22(7):1105-1116. PubMed ID: 31728833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.